Enable Injections

Executive Summary

Enable Injections, founded in 2010 and headquartered in Cincinnati, is a private healthcare innovation company specializing in high-volume wearable drug delivery systems. Its flagship technology, the enFuse® On-Body Platform, is designed to deliver large volumes of medication subcutaneously in a hands-free manner, offering a comfortable alternative to traditional intravenous infusions. The platform aims to enhance patient convenience, reduce healthcare costs, and enable at-home administration of biologics and other high-volume therapies. By focusing on the growing demand for self-administered treatments, Enable Injections addresses a critical need in the expanding biologics market, where many drugs require frequent or prolonged infusions. The company's enFuse platform has the potential to partner with multiple pharmaceutical companies to deliver their biologic drugs, similar to wearable injectors like those from Insulet or West Pharmaceutical Services. Recent developments include strategic collaborations with drug developers to integrate the enFuse device with their pipeline therapies. As the trend toward decentralized clinical trials and home healthcare accelerates, Enable Injections is well-positioned to capture market share. The company's ability to secure FDA clearances or partnerships with major pharma could significantly enhance its valuation. Given the lack of public financial details, conviction in Enable Injections' future success hinges on execution and upcoming milestones.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance for enFuse Platform75% success
• Q4 2026Announcement of Major Pharmaceutical Partnership60% success
• Q1 2027Completion of Phase 1 Study for Lead Drug-Device Combination80% success